Compare IGI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IGI | ACOG |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.0M | 110.4M |
| IPO Year | 2009 | N/A |
| Metric | IGI | ACOG |
|---|---|---|
| Price | $16.07 | $6.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 12.4K | ★ 76.2K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.78 | $4.50 |
| 52 Week High | $17.09 | $10.88 |
| Indicator | IGI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 61.56 |
| Support Level | $15.78 | $6.46 |
| Resistance Level | $16.59 | $7.69 |
| Average True Range (ATR) | 0.14 | 0.54 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 24.61 | 63.64 |
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.